VivoSeq
Other

Liver

0

Pipeline Programs↗

25

Active Trials↗

24

Companies Involved↗

Liver is an early-stage landscape with 0 programs across 24 companies. The most active players are Boehringer Ingelheim, Eli Lilly, Roche.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

36/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalUCB logo

UCB

0 programs

PreclinicalA

Agile Therapeutics

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

136

clinical trials

Completed86 · 63%
Recruiting15 · 11%
Unknown status10 · 7%
Withdrawn7 · 5%
Terminated6 · 4%
Not yet recruiting6 · 4%
Other6 · 4%

Clinical Trials

Trial Activity

136 trials

Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects
Recruiting·GGH Research Ireland Limited·Phase 1·NCT06511947·52 enrolled
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT07023354·32 enrolled
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
Recruiting·GGanzhou Hemay Pharmaceutical Co., Ltd·Phase 1·NCT06376474·24 enrolled
Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time and Factorial Assays in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage.
Recruiting·UUniversity Hospital, Strasbourg, France·N/A·NCT06705829·100 enrolled
Identification of New Tools for Predicting Natural Metabolic Performance of the Liver
Recruiting·—·Phase 1·NCT07014930·40 enrolled
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07401862·36 enrolled
Detoxification of the Liver In PSC (Dolphin)
Recruiting·—·Phase 2·NCT05835505·28 enrolled
177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
Recruiting·UUniversity of Iowa·Phase 2·NCT06395402·120 enrolled
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
Recruiting·KKelley-Ross & Associates, Inc.·Phase 4·NCT07210125·75 enrolled
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
Recruiting·Roche logoRoche·Phase 1·NCT07214766·312 enrolled
Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs
Recruiting·—·Phase 4·NCT06816342·120 enrolled
The DART DELIVER-02 Study
Recruiting·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT07217379·24 enrolled
Attitudes, Perceptions, Clinical Practice, and Barriers in Diagnosis and Management of Patients With Metabolic Dysfunction-associated Steatotic Liver Disease: a Cross-sectional Survey on Physicians in China
Recruiting·Novo Nordisk logoNovo Nordisk·N/A·NCT07682363·470 enrolled
Augmented Reality Real-Time Guidance for MRI-Guided Interventions
Recruiting·MMayo Clinic·Preclinical·NCT07120906·20 enrolled
Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database
Recruiting·SState University of New York at Buffalo·N/A·NCT02897908·1,000 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)